The AbATE clinical trial is testing an experimental therapy known as hOKT3γ1(Ala-Ala) to determine whether it can halt the progression of type 1 diabetes in newly diagnosed individuals. The study is taking place at 6 clinical centers in the U.S. and is seeking individuals between the ages of 8-30 who have been diagnosed with type 1 diabetes within the past 6 weeks.
(TrialNet)
Effects of rituximab on the progression of type 1 diabetes in new onset subjects
The goal of the study is to find out if the medicine rituximab can prevent further beta cell destruction. Rituximab has been successfully used in other illnesses to slow down the immune response. TrialNet researchers hope it will help here to scale down the attack on beta cells and allow them to keep making insulin. Even if rituximab works, you will still need to take insulin but your blood sugar (glucose) should be easier to control.
This will be an early phase II study of the safety and efficacy of the rabbit polyclonal anti-thymocyte globulin Thymoglobulin (Thymo) in new onset Type 1 diabetes mellitus (T1DM) to determine if this treatment can induce tolerance and thereby prolong endogenous insulin secretion in affected individuals. Note that this study is not currently enrolling patients.
|
